Colomer R, Ruibal A, Navarro M, Encabo G, Sole L A, Salvador L
Section of Medical Oncology, Valle de Hebron General Hospital, Barcelona, Spain.
Int J Biol Markers. 1986 May-Aug;1(2):89-92.
CA 15.3 is an antigen expressed by human breast carcinoma cells, and defined by two monoclonal antibodies, 115D8 and DF3. We used IRMA to determine the circulating serum levels of CA 15.3 in 1178 subjects with breast cancer, non-breast malignancies, benign diseases and controls. A threshold level of 40 U/ml was established with 140 healthy controls and 650 patients with benign diseases (respectively 0% subjects and 1.5% patients had abnormal antigen levels). Elevated CA 15.3 was found in 12 of 184 patients with malignancies different from breast cancer (6.5%), either epithelial carcinomas with distant metastases, mainly in the liver, or primary liver tumors. Breast cancer patients (n = 204) were analysed by prior therapy, UICC stage and WHO response to therapy. Eight of 134 (5.9%) patients with stage II or III breast cancer at presentation and no evidence of disease (NED) had elevated CA 15.3. All of 22 patients with stage IV breast cancer not responding to therapy (SD and PD) had antigen levels greater than 40 U/ml, as did 10 of 34 (29.4%) stage IV patients in objective response (CR + PR). Three of 14 pretreatment patients had abnormal marker levels, and they later proved to have distant metastases. Serum CA 15.3 values were statistically different (p less than 0.01) in NED (20.6 +/- 11.2 U/ml), CR + PR (33.5 +/- 24.0 U/ml), stable disease (98.8 +/- 50.4 U/ml) and progressive disease (greater than 200 U/ml) breast cancer patients. Our results suggest that circulating CA 15.3 antigen levels agree with the stage of breast cancer and with the response to therapy.
CA 15.3是一种由人乳腺癌细胞表达的抗原，由两种单克隆抗体115D8和DF3所界定。我们采用免疫放射分析法（IRMA）测定了1178名患有乳腺癌、非乳腺恶性肿瘤、良性疾病的受试者以及对照组受试者血清中CA 15.3的循环水平。通过140名健康对照者和650名患有良性疾病的患者确定了40 U/ml的临界值（分别有0%的对照者和1.5%的患者抗原水平异常）。在184名患有非乳腺癌恶性肿瘤的患者中，有12名（6.5%）CA 15.3升高，这些患者包括伴有远处转移的上皮癌，主要转移至肝脏，或原发性肝癌。乳腺癌患者（n = 204）根据既往治疗、国际抗癌联盟（UICC）分期和世界卫生组织（WHO）的治疗反应进行分析。134名初诊时为II期或III期乳腺癌且无疾病证据（NED）的患者中有8名（5.9%）CA 15.3升高。22名对治疗无反应（疾病稳定和疾病进展）的IV期乳腺癌患者的抗原水平均高于40 U/ml，在客观缓解（完全缓解+部分缓解）的34名IV期患者中有10名（29.4%）也是如此。14名治疗前患者中有3名标志物水平异常，后来证实有远处转移。在NED（20.6±11.2 U/ml）、完全缓解+部分缓解（33.5±24.0 U/ml）、疾病稳定（98.8±50.4 U/ml）和疾病进展（大于200 U/ml）的乳腺癌患者中，血清CA 15.3值存在统计学差异（p小于0.01）。我们的结果表明，循环CA 15.3抗原水平与乳腺癌分期及治疗反应相符。
